Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · ProShares

ProShares Ultra Health Care (RXL)

Ticker RXL · · Holdings as of May 31, 2026

Expense ratio
0.95%$95/yr per $10k
5-yr return
+7.2%annualized
1-yr return
+19.7%as of Dec 2025
Net assets
$72.1Mall share classes
Holdings
70

Bottom line

Is RXL a good fund? The bottom line

RXL is an actively managed health care sector ETF from ProShares.

Its expense ratio is 0.95% — about $95 a year on every $10,000 invested, cheaper than 50% of health care sector funds we track.

It returned +19.7% over one year, +7.2% a year over five years, +12.6% a year over ten (as of Dec 31, 2025, per its prospectus).

With $72.1 million in net assets and 70 holdings, its largest position is Eli Lilly & Co. (12.7%) and the top 10 make up 57.8% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 78% top-holdings overlap).

What stands out

  • 5-year return beat 88% of category peers

What to watch

  • Concentrated: top 10 holdings are 57.8% of assets

Updated Nov 19, 2026

What RXL invests in

ProShares Ultra Health Care (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the S&P Health Care Select Sector Index (the Index).

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of health care companies included in the S&P 500 Index. The S&P 500 Index is designed to measure the performance of 500 of the largest companies listed and domiciled in the U.S. The Index includes health care companies in the following industries according to the Global Industry Classification Standard (GICS): health care equipment & supplies, health care providers & services; health care technology; biotechnology; pharmaceuticals; and life sciences tools & services. These companies are then weighted based on market capitalization. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March, June, and December. The Index is…

From the fund's prospectus (filed Sep 25, 2026).

RXL performance

Fund calendar-year total returns, 2016–2025 2016: −8.9%; 2017: +46.0%; 2018: +5.4%; 2019: +38.9%; 2020: +19.2%; 2021: +47.8%; 2022: −15.1%; 2023: −3.2%; 2024: −2.7%; 2025: +19.7% −9% 2016 +46% 2017 +5% 2018 +39% 2019 +19% 2020 +48% 2021 −15% 2022 −3% 2023 −3% 2024 +20% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
RXL+19.7%+7.2%+12.6%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full RXL performance history →

What RXL costs

On a $10,000 investment, RXL's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,305 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full RXL fee table →

RXL top 10 holdings

#Holding% of fund
1Eli Lilly & Co.12.67%
2ProShares GENIUS Money Market ETF11.81%
3Johnson & Johnson7.86%
4AbbVie, Inc.5.57%
5UnitedHealth Group, Inc.4.98%
6Merck & Co., Inc.4.26%
7Repurchase Agreement2.91%
8Thermo Fisher Scientific, Inc.2.68%
9Amgen, Inc.2.62%
10Gilead Sciences, Inc.2.41%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 57.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to RXL

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%78% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%78% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%76% Compare
iSharesIXJ iShares Global Healthcare ETF0.38%73% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%51% Compare
SchwabSWHFX Schwab Health Care Fund0.8%68% Compare

More funds like RXL →

RXL FAQ

What is the expense ratio of RXL?
RXL's expense ratio is 0.95%, which works out to about $95 a year for every $10,000 invested. The prospectus estimates total costs of $1,305 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RXL a good investment?
It depends on your goals, but the data points to: 5-year return beat 88% of category peers; concentrated: top 10 holdings are 57.8% of assets. This is general information, not personalized advice.
What does RXL hold?
RXL's largest holdings are Eli Lilly & Co. (12.7%), ProShares GENIUS Money Market ETF (11.8%), Johnson & Johnson (7.9%), AbbVie, Inc. (5.6%), UnitedHealth Group, Inc. (5.0%). It holds 70 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is RXL's 5-year return?
RXL returned +7.2% a year over the five years ending Dec 31, 2025, and +12.6% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to RXL?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 78% with RXL and charges 0.08%.
Who manages RXL?
RXL is offered by ProShares through Proshares Trust.